Targeting Nuclear Export Proteins in Multiple Myeloma Therapy.
- Published in:
- BioDrugs, 2022, v. 36, n. 1, p. 13, doi. 10.1007/s40259-021-00514-6
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2022 AND VI 36 AND IP 1
Results: 7
1
2
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.
- Published in:
- BioDrugs, 2022, v. 36, n. 1, p. 55, doi. 10.1007/s40259-021-00513-7
- By:
- Publication type:
- Article
3
A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease.
- Published in:
- BioDrugs, 2022, v. 36, n. 1, p. 85, doi. 10.1007/s40259-021-00512-8
- By:
- Publication type:
- Article
4
SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
- Published in:
- BioDrugs, 2022, v. 36, n. 1, p. 41, doi. 10.1007/s40259-021-00511-9
- By:
- Publication type:
- Article
5
Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System.
- Published in:
- BioDrugs, 2022, v. 36, n. 1, p. 1, doi. 10.1007/s40259-021-00510-w
- By:
- Publication type:
- Article
6
Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians.
- Published in:
- BioDrugs, 2022, v. 36, n. 1, p. 71, doi. 10.1007/s40259-021-00509-3
- By:
- Publication type:
- Article
7
Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review.
- Published in:
- BioDrugs, 2022, v. 36, n. 1, p. 27, doi. 10.1007/s40259-021-00508-4
- By:
- Publication type:
- Article